Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Euvichol-Plus + Typbar-TCV + MR vaccine
- Development stage
- Unknown
- Lead developer
- EuBiologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
This combination vaccine regimen consists of three distinct vaccines: **Euvichol-Plus** (an oral, bivalent, killed whole-cell cholera vaccine), **Typbar-TCV** (a typhoid conjugate vaccine consisting of Vi-polysaccharide conjugated to a tetanus toxoid carrier), and a live-attenuated **measles-rubella (MR) vaccine**. The regimen is being evaluated by the **International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)** in a randomized, non-inferiority clinical trial (NCT05144620) to assess the safety and immunogenicity of co-administering these vaccines in children aged 12 to 59 months. Euvichol-Plus targets *Vibrio cholerae* serogroups O1 and O139, Typbar-TCV targets *Salmonella Typhi*, and the MR vaccine targets the measles and rubella viruses. This co-administration strategy is intended to simplify immunization schedules and improve vaccine coverage in regions where these diseases are endemic.
- Brand names
- Euvichol-PlusTypbar-TCV
- Other names
- OCV + TCV + MR vaccineOral Cholera Vaccine + Typhoid Conjugate Vaccine + Measles-Rubella Vaccineoral cholera vaccine-International Centre for Diarrhoeal Disease Research, Bangladesh-cholera-typhoid-measles-rubella
02
Targets
Vi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on Euvichol-Plus + Typbar-TCV + MR vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Euvichol-Plus + Typbar-TCV + MR vaccine.